Skip to content

Dual-focus Soft Contact Lenses for Controlling Rapid Progressive Myopia in Young Adults

The Effectiveness and Acceptability of Dual-focus Soft Contact Lenses for Controlling Rapid Progressive Myopia in Young Adults: A Randomized Controlled Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06528860
Enrollment
144
Registered
2024-07-30
Start date
2024-08-31
Completion date
2027-09-30
Last updated
2024-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Keywords

Myopia, Dual-focus contact lenses, Young adults, Adult myopia progression

Brief summary

This study aims to evaluate the effectiveness and acceptability of dual-focus soft contact lenses in controlling rapid myopia progression in adults through a randomized controlled trial. By applying myopia control measures to the adult population, we hope to provide scientific evidence for the effective control of adult myopia progression and offer insights into the understanding of myopia progression during early adulthood.

Detailed description

It has long been believed that the progression of myopia mainly occurs during the elementary to high school stages. However, some studies and clinical practice suggest that a considerable proportion of adults still experience myopia progression in their adulthood, especially in those who have prolonged near work or screen usage time. At present, there is insufficient evidence on whether these population needs myopia control intervention. Most adults experiencing myopia progression do not receive appropriate myopic intervention measures, leading to an increase of dioptre, which may affect the quality of daily life, and raise the risk of high myopia and blinding myopia complications. This study aims to evaluate the effectiveness and acceptability of dual-focus soft contact lenses in controlling rapid myopia progression in adults through a randomized controlled trial. By applying myopia control measures to the adult population, we hope to provide scientific evidence for the effective control of adult myopia progression and offer insights into the understanding of myopia progression during early adulthood.

Interventions

DEVICEMiSight® 1 day soft contact lenses

Dual-focus contact lenses, daily disposable, material: omafilcon A, water content: 60%.

DEVICEProclear® 1 day soft contact lenses

Single-vision contact lenses, daily disposable, material: omafilcon A, water content: 60%.

Sponsors

Shanghai Eye Disease Prevention and Treatment Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Masking description

This study will utilize a Central Randomization System (CRS) for the random grouping and glasses allocation of study subjects during the clinical trial. Investigators and participants will be blinded to the intervention received until unblinding.

Intervention model description

Intervention Group: Daily disposable bifocal soft corneal contact lenses: MiSight® 1 day soft contact lens (CooperVision, material: omafilcon A, water content: 60%). Control Group: Daily disposable single-focus soft corneal contact lenses: Proclear® 1 day soft contact lens (CooperVision, material: omafilcon A, water content: 60%)

Eligibility

Sex/Gender
ALL
Age
18 Years to 25 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-25 years; * Myopia progression \<= -0.50D in either eye in the past year (evaluated by -manifest refraction); * The subject eye: cycloplegic spherical equivalent ranges from -2.00D to -6.0D and cylinder power doesn't exceed -1.50D; * The subject eye's best corrected visual acuity \<= logMAR 0.1; * Anisometropia does not exceed 1.50D.

Exclusion criteria

* Current use of MC interventions or prior use of MC interventions within the past 6 months; * Disease or anatomical factors that affect the wearing of contact lenses; * History of myopia correction surgery; * Suffering from ocular or systemic diseases that may be related to myopia, such as Marfan syndrome, retinopathy of prematurity, diabetes, etc.; * pregnant female; * Other conditions deemed unsuitable by the investigators.

Design outcomes

Primary

MeasureTime frameDescription
Change in cycloplegic spherical equivalent after 2 years2 years after the baselineThe difference in the change of cycloplegic spherical equivalent between the intervention group and the control group.

Secondary

MeasureTime frameDescription
Change in axial length after 2 years2 years after the baselineThe difference in the change of axial length between the intervention group and the control group.

Countries

China

Contacts

Primary ContactXiangui He
xianhezi@163.com(86)15000755422
Backup ContactHotin Wu
24499980@sjtu.edu.cn(86)19821287621

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026